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Background: The role of serine/threonine kinase 33 (STK33) gene in tumorigenesis is still controversial. This study
was aimed to investigate whether STK33 had the effect on hypopharyngeal squamous cell carcinoma (HSCC) and
relevant genes, as well as the potential relation to ERK1/2 pathway.
Methods: Immunohistochemistry was performed to investigate STK33 expression in human HSCC specimens. MTT,
immunofluorescence, clone formation and matrigel invasion assays were employed to detect the effects of STK33
knockdown (STK33-RNAi) and/or PD98059 on major oncogenic properties of a HSCC cell line (Fadu), while, real-time
PCR and western blot were used to examine the expressions of relevant genes.
Results: STK33 was over-expressed in HSCC specimens, which was significantly associated with certain clinicopathological
parameters. STK33-RNAi in Fadu cells resulted in inhibition of proliferation, induction of apoptosis, reduction of clone
formation, and decline in the migration and invasion. These effects were potentiated by administration of PD98059.
Mechanistic studies revealed that STK33-RNAi led to an increase in Caspse-3, Nm-23-H1 and E-Cadherin expressions
and a reduction in Bcl-2, Ki-67 and Vimentin expressions. Moreover, PD98059 significantly reduced both ERK1/2 and
STK33 expressions in Fadu cells.
Conclusions: STK33 is a potential oncogene and a promising diagnostic marker for HSCC. STK33 may promote
tumorigenesis and progression of HSCC, and serve as a valuable molecular target for treatment of HSCC.
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Hypopharyngeal squamous cell carcinoma (HSCC), which
originates from a subsite of the upper aerodigestive tract,
accounts for 2-6% of head and neck cancers, the 6th most
common cancer in the world [1,2]. As this type of cancer
is initially diagnosed at an advanced stage, thus, therapy
for this tumor is one of the most formidable challenges in
human malignancies. As such, studies of the molecular
biology of this disorder are key issues to get insight into
the mechanistic underpinnings of how incipient cells be-
come tumorigenic and malignant ultimately, which may,
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unless otherwise stated.advanced hypopharyngeal cancer, with more expectation
of both survival improvement and maximum preservation
of hypopharyngeal function. While numerous genetic and
epigenetic factors have been found to be involved in the
pathogenesis of HSCC, the molecules that participate in
tumorigenesis of this kind of carcinoma are still known
little. More recently, compelling evidence has indicated
the involvement of serine/threonine kinase 33 (STK33)
gene in tumorigenesis [3,4].
STK33 gene encodes a serine/threonine kinase [5],
which is subsequently identified as a member of the
calcium⁄ calmodulin dependent kinase (CAMK) family
[6]. Of note, STK33 involves in the “synthetic lethal”
process of a variety of tumor cells, which depends on
the Ras oncogene [4]. This finding implies that STK33
might possess an important value in molecular target
therapy for KRAS-dependent tumors. However, a newThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 HSCC patients’ clinicopathological characteristics
and IHC staining for STK33
N STK33 IHC scorea P valueb
Age
<60 years 13 13.69 ± 4.23 0.8988
≥60 years 17 14.12 ± 2.98
Sex
Male 28 13.96 ± 3.65 0.8255
Female 2 13.50 ± 2.12
Differentiationc
Keratinizing 888 12.95 ± 3.36 0.0044*
Non-keratinzing 552 15.61 ± 3.04
Tumor size
≤2 cm 23 12.83 ± 3.27 0.0011*
>2 cm 7 17.57 ± 1.13
Clinical stage
I 9 9.78 ± 2.11 <0.0001*
II 4 14.25 ± 2.87
III 5 15.60 ± 2.51
IV 12 16.25 ± 2.01
Lymph node metastasis
Negative 24 13.29 ± 3.62 0.048*
Positive 6 16.50 ± 1.64
aSTK33 IHC score showed as mean ± standard deviation.
bMan-Whitney U test for two groups or one-way ANOVA for > two groups.
cThe number was fields of observation by microscope.
*Statistically significant, P < 0.05.
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KRAS-dependent cancer cells [7,8]. The pro and con evi-
dence indicates that the role of STK33 in tumor cells re-
mains controversial and, from another angle, reflects that
the mechanism underlying the action of STK33 to alter
the nature of tumor may be much more complex [7-9].
In comparison to the other members of CAMK family,
which are well known to phosphorylate a wide range of
substrates and regulate numerous cellular functions [10],
the precise mechanism underlying the actions of STK33,
especially, on survival or signaling pathways on tumor
cells, however, has been studied sparingly as yet. It has
been confirmed that mitogen-activated protein kinase
(MAPK) system, which comprises a cluster of a serine/
threonine protein kinases, represents one of the most
classical signal transduction pathways [11]. Almost all
eukaryotic cells possess multiple MAPK pathways,
which generally regulate a variety of cell activities in
response to different stimuli. Particularly, extracellular
signal-regulated protein kinases 1 and 2 (ERK1/2), the
members of the MAPK family, is able to mediate cell
proliferation, survival, differentiation and motility etc.
[12], and thus, is widely used throughout evolution in
many physiological and pathological processes.
To date, no study has been conducted to investigate
STK33 expression in human HSCC as well as the relation-
ship between the STK33 gene and ERK1/2 pathway in car-
cinogenesis of HSCC. With these points in mind, we firstly
examined the expression of STK33 in human HSCC speci-
men and its association with clinicopathological character-
istics and, then, explored whether STK33 gene could affect
the biological traits, such as apoptosis, proliferation, metas-
tasis and invasion, as well as epithelial mesenchymal transi-
tion (EMT) in Fadu cells, a cell line of human HSCC, and
its relationship with ERK1/2 signaling pathway.
Methods
Carcinoma specimens
HSCC specimens and corresponding adjacent normal tis-
sues were obtained from 30 patients who underwent oper-
ations at General Hospital of Ningxia Medical University
(Yinchuan, P.R. China) from 2010 to 2013. Patients had
received neither adjuvant chemotherapy nor radiotherapy
prior to surgery. The pathological analysis was conducted
according to criteria issued by World Health Organization
(WHO) [13]. Tumor clinical stage was defined according
to criteria by American Joint Committee on Cancer
(AJCC) [14]. All the detailed information and clinicopath-
ological parameters of patients in this series were provided
in Table 1. This study was reviewed and approved by the
Institute Research Ethics Committee of General Hospital
of Ningxia Medical University, Yinchuan, P. R. China.
All patients provided written informed consent for this
research.Immunohistochemistry (IHC) and haematoxylin and eosin
(HE) staining
Tumor tissues and patient-matched normal hypopharyn-
geal tissues were fixed in 10% neutral-buffered formalin
and embedded in paraffin blocks. 4-μm serial sections
were cut, then, IHC and HE staining were carried out.
Briefly, tissue sections were performed with citrate buf-
fer (PH = 6.0) and 1.5% hydrogen peroxide in methanol.
Slides were incubated with anti-STK33 (1:100, Santa
Cruz, CA, USA) at 4°C overnight, then, with second
antibody (ZSGB, Beijing, China) at room temperature
for 1 h. 3,3’-diaminobenzidine (DAB) was used for visua-
lization of the immunoreaction. As for the HE staining,
the sections were stained with hematoxylin and eosin re-
spectively. The process of dehydration, transparence and
mounting was similar to that of IHC.
A semiquantitative scoring system named “H-score
approach” was used to evaluate the expression level of
STK33 [15]. The proportion of epithelial cells staining
positively was termed category A and was assigned
scores from 1 to 6 (A = 1 (0-4%); 2 (5-19%); 3 (20-39%); 4
(40-59%); 5 (60-79%); 6 (80-100%). Intensity of staining
was termed category B and was scored as 0 (negative);
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ment, all fields were observed at × 400 magnification [16].
A final score was calculated by multiplying A by B (mini-
mum 0, maximum 18). Meanwhile, the average score of
each case was obtained.
Cell culture
The human HSCC cell line, Fadu cells, was purchased
from Biosis (Shanghai, China). Fadu cells were cultured
in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum at 37°C in a humid atmos-
phere containing 5% CO2. Cells were treated with 1 to
10 μM PD98059 (an inhibitor of ERK1/2, Sigma, MO,
USA).
Construction of STK33-RNAi lentiviral vector and transfection
into Fadu cells
A STK33-RNA interference (STK33-RNAi) lentiviral
vector (GV115-GFP-STK33 shRNA) was constructed by
GeneChem Co, Ltd (Shanghai, China) and a GFP-
lentiviral vector (GV115-GFP) was used as a negative
control (Mock RNAi). In brief, after identification of the
target sequence of STK33-RNAi (NM_030906, CTCAA-
GAACCTCAAATGTA), double-stranded oligonucleo-
tides encoding human STK33-vshRNA were annealed
and inserted into the small hairpin RNA (shRNA) ex-
pression vector GV115-GFP. Next, the lentiviral titers of
STK33-RNAi and control mock RNAi were identified. In
order to detect the efficiency of transfection in Fadu
cells, 2 × 104 Fadu cells were seeded into 15 mm plate
specially used for laser scanning confocal microscope
and incubated for 24 h. GV115-GFP-STK33-shRNA and
GV115-GFP, which were diluted with 270 μl 10% FBS
and 30 μl polybrene (50 μg/ml, Sigma, MO, USA), pre-
treated Fadu cells for 12 h. Subsequently, the solution
was replaced with 10% FBS-DMEM. Transfected Fadu
cells were observed with laser scanning confocal micros-
copy everyday.
Assessment for cell viability
The 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium
Bromide (MTT) assay was used to evaluate the cell viabil-
ity. In brief, 3 × 104/ml (100 μl per well) Fadu cells were
seeded in 96-well culture plate and incubated for 24 h,
then, replaced with fresh medium containing different con-
centrations of PD98059 (0, 1, 5, and 10 μM) for another
24, 48 and 72 h incubation, respectively. With respect to
the effect of STK33-RNAi related groups, after Fadu cells
were transfected with mock RNAi and 1 × 107 TU/ml
STK33-RNAi for 48 h, cells were subjected to 0 and 5 μM
PD98059 for another 48 h. Then, 20 μl MTT (5 mg/ml)
was added into each well and incubated at 37°C for add-
itional 4 h. Subsequently, the supernatant was removed,
100 μl DMSO was added into each well and shaken foranother 20 min until the crystals were dissolved. The
optical density (OD) values were measured at 570 nm
using an ELISA reader (Multiskan MK3, Finland). Cell via-
bility was calculated according to the following formula:
Cell relative viability %ð Þ¼ ODexperiment=ODcontrol
100% ODblankis adjusted to zeroð Þ
Morphological examination by Ho.33342 (HO) and
Propidium Iodide (PI) double fluorescent staining
2 × 104 Fadu cells/ml were seeded in dishes (20 mm) for
24 h. Cells were transfected with mock RNAi and 1 ×
107 TU/ml STK33-RNAi for 48 h followed by the ad-
ministration of 0 and 5 μM PD98059 for another 48 h.
Then, cells were washed twice by PBS, fixed with 95%
alcohol for 10 min, and stained by Ho (10 μg/ml) and PI
(50 μg/ml) at 37°C for 30 min. Laser scanning confocal
microscopy was used to observe the morphological
changes of Fadu cells with green light (488 nm) for blue
nucleus and red light (532 nm) for red cells respectively,
later, the two pictures were integrated together as one.
The number of dead cells within every 200 cells were
counted [17].
Colony formation assay
500 cells/per pore were seeded into 6-well plate and cul-
tured for 24 h. Next, cells were transfected with mock
RNAi and 1 × 107 TU/ml STK33-RNAi for 48 h and cells
were treated with 0 and 5 μM PD98059 every 3 d till 10
d. Then, cells were washed twice with PBS, fixed with
95% alcohol for 10 min and stained with crystal violet
for 10 min, subsequently, washed with water till the
plates were clear. Finally, the number of colonies where
the number of cells exceeded 50 was counted [18].
Assessment of cell migration and invasion
A Costar Transwell chamber (Corning, NY, USA) was
employed to assess cell migration. As for cell invasion
assay, the membrane was covered with matrigel (BD,
MA, USA). Firstly, Fadu cells were transfected with
mock RNAi and 1 × 107 TU/ml STK33-RNAi for 48 h.
Then, 100 μl (1 × 104/ml) cell suspension with serum-
free DMEM, which simultaneously contained PD98059
at final concentrations of 0 and 5 μM, was individually
added into the upper chamber and 500 μl complete
medium was consistently placed into the lower chamber.
These cells were incubated at 37°C for 48 h, washed with
PBS and fixed by methanol. Then, cells remaining on
the upper surface of the filter membrane were completely
removed, while, the cells still on the opposite surface of
the filter membrane were stained with crystal violet for
10 min. The migratory cells were then observed and
counted in six random fields (Magnification 100×).
Huang et al. BMC Cancer  (2015) 15:13 Page 4 of 12mRNA extraction and real-time PCR analysis
Fadu cells (1.5 × 105 cells/ml, 1 ml) were cultured in
6-well culture plates for 24 h. Then, cells were transfected
with mock RNAi and 1 × 107 TU/ml STK33-RNAi lenti-
viral vector for 48 h and cells were treated with 0 and
5 μM PD98059 for another 48 h. These cells were collec-
ted for extracting the total RNA with Trizol (Invitrogen,
USA). Then, mRNA was reverse transcribed into cDNA
(Fermentas, Ontario, Canada) and SYBR Green real-time
PCR (Takara, Dalian, China) assay was employed. PCR
primers (Sangon Biotech, Shanghai, China) for the genes
were listed in Table 2. The conditions were as follows:
pre-degeneration at 95°C for 2 min, degeneration at 95°C
for 15 sec, renaturation at different temperatures (Table 2),
elongation at 72°C for 40 sec, total 40 cycles. The data
were analyzed using the Realplex2 Real-Time PCR System
(Eppendorf, Hamburg, Germany). The real-time PCR ex-
periments with every gene were carried out in triplicate,
and Mean ± SEM was used for the determination of
mRNA levels. By use of the comparative Ct method with
GAPDH as the reference gene, relative quantification of
the mRNA levels was performed with the formula 2-△△Ct.
Protein extraction and western blot analysis
Fadu cells (1.5 × 105 cells/ml, 1 ml) were cultured in
6-well culture plates for 24 h. Subsequently, cells were
transfected with mock RNAi and 1× 107 TU/ml STK33-
RNAi lentiviral vector for 48 h and cells were treated with
0 and 5 μM PD98059 for another 48 h. These cells were
used to extract the total protein with lysis buffer (PMSF:
RIPA = 1:100) and the concentration of protein was mea-
sured with the BCA protein assay kit (Beyotime, Shanghai,
China). 35 μg protein was separated by 6% (Ki-67), 10%
(E-Cadherin), 12.5% (Vimentin, STK33, β-Actin, ERK1/2)
and 15% (Caspase-3, Bcl-2, Nm-23-H1) SDS-PAGE gels.
After electrophoresis, transmenbrane and blockage, the
PVDF membranes (Millipore, USA) were incubated with
primary antibodies overnight at 4°C (anti-STK33: 1:400,
anti-Caspase-3: 1:400, anti-Bcl-2: 1:400 (Santa Cruz, CA,
USA), anti-ERK1/2: 1:400, (Abcam, Cambridge, USA),Table 2 Primer, amplicon size and annealing temperature of
Gene Forward 5′to3′ Reverse 5′to3′
STK33 CCCCGACTGTTCATCTGCTTCT TGCCCACTTCGTTTCTGTTTCC
ERK1/2 TCCAAGGGCTACACCAAGTC CTCGTCACTCGGGTCGTAAT
Caspase-3 CAGAACTGGACTGTGGCATTG GCTTGTCGGCATACTGTTTCA
Bcl-2 GTGGCCTTCTTTGAGTTCGG TCCACAGGGCGATGTTGTC
Ki-67 TGTCACATCGCTATTTCAAATTCAG GGAGGGCTTGCAGAGCATTTA
E-Cadherin GGGGTCTGTCATGGAAGGTGCT GTAAGCGATGGCGGCATTGTA
Vimentin AGGCAGAAGAATGGTACAAATCC TTTAAGGGCATCCACTTCACA
Nm-23-H1 CTGGGACCATCCGTGGAGACT TCCTCAGGGTGAAACCACAAG
GAPDH AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTanti-E-Cadherin: 1:300, anti-Vimentin: 1:10000, anti-Nm-
23-H1: 1:2000, (Epitomics, Calfornia, USA), anti-Ki-67:
1:500, and anti-β-Actin: 1:2000 (Biosynthesis, Beijing,
China). Then, the membranes were incubated with the
secondary antibody (1:2000) at room temperature for 1 h.
Finally, the immunoblots were developed using ECL re-
agents (Santa Cruz, CA, USA) and detected after exposure
to X-ray film. Densitometer readings were carried out to
quantitate the immunoreactive bands. The ratios of related-
genes to β-actin were then determined.
Statistical analysis
The STK33 IHC scores of each subgroup of clinicopath-
ological parameters in Table 1 were shown as mean ±
standard deviation (SD). The Man-Whitney U test was
applied for comparisons between two groups, while,
one-way analysis of variance (ANOVA) was used to
compare more than two groups. The other data were
presented as mean ± standard error of mean (SEM) of
separate experiments (n ≥ 3) and statistically analyzed
by one-way ANOVA. Statistical calculations were perfor-
med using SPSS software package for Windows (version
13.0; SPSS, Chicago, IL). P value of less than 0.05 was
considered significant.
Results
STK33 expression increased in human HSCC specimens
and activated in Fadu cells
The expression of STK33 in human normal and hypo-
pharynx tumor tissue was examined by IHC. As shown
in Figure 1A, B STK33 protein was localized in nucleus
and, partly, in cytoplasm in all specimens. With respect
to the staining intensity, normal tissue, cancer in situ
(CIS), and invasive cancer (IC) displayed weak, moderate
and strong immunoreactivity for STK33 protein, respect-
ively. STK33 IHC score was significantly decreased in
normal tissue (4.17 ± 3.38) compared with that in CIS
(11.63 ± 3.56, P < 0.05) or IC (13.97 ± 3.47, P < 0.05). In
contrast, there was statistical difference in STK33 IHC
score between CIS and IC (P < 0.05).each gene for qRT-PCR
Product length/bp Tm/°C Genbank NCBI reference sequence
391 54 Nm_030906.2
363 60 Nm_002745.4
192 54 Nm_004346.3
88 55 Nm_000633.2
TC 170 54 Nm_001145966.1
G 103 57 Nm_004360.3
G 146 55 Nm_003380.3
C 112 55 Nm_000269.2
CA 130 55 Nm_001289746.1
Figure 1 Expression of STK33 in human HSCC tissue and Fadu cells. (A) Representative imagines of STK33 IHC staining and matched H&E
staining in hypopharyngeal normal and tumor tissues. a) Low STK33 expression in normal tissue; b) Moderate STK33 expression in CIS; and c)
High STK33 expression in IC (Magnification × 400, Scale bars, 50 μm) (B) IHC score of STK33 expression in samples shown in A. Data were
expressed as the mean ± SD. * P < 0.05. (C, D) The STK33 mRNA and protein were expressed abundantly in Fadu cells as determined by qRT-PCR
and western blot.
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initially examined at both mRNA and protein levels. As
shown in Figure 1C, D STK33 mRNA expression in
Fadu cells was apparent from the RT-PCR data and, cor-
respondingly, similar situation for STK33 protein expres-
sion was found by western blot.
Correlation of STK33 expression with clinicopathological
characteristics
The clinicopathological characteristics of the patients
with HSCC and analyses of STK33 immunostaining were
summarized in Table 1 (Figure 2). Histopathologically,
the tumors are traditionally graded into keratinizing and
non-keratinizing SCC. Keratinizing type is characterized
by large tumor island with variable “pearl” formation
pushing margins. Non-keratinizing SCC is characterized
by scattered small irregular cords or single tumor cells,
with poorly defined infiltrating margins [17]. In the pre-
sent study, IHC staining showed that the intensity of
STK33 expression was much stronger in non-keratinizing
type than keratinizing type of HSCC, with a statistically
significant difference in IHC score between the two differ-
ent types (P < 0.05). In addition, STK33 IHC scores weremarkedly increased in HSCC specimens in size >2 cm,
compared with those ≤ 2 cm (P < 0.05). Also, IHC
score of STK33 was significantly higher in patients at
advanced HSCC stages (stageII, III and IV) than that in
stageI (P < 0.05). Similarly, IHC score was significantly
increased with metastasis to the lymph nodes compared
with non-metastasis (P < 0.05). There were no other signi-
ficant correlations between STK33 expression with patient
age or with sex.
Effects of STK33-RNAi and/or PD98059 on cell viability,
apoptosis and colony formation in Fadu cells
As shown in Figure 3A-C, green fluorescence in Fadu
cells was increased in a time-manner after the transfec-
tion. Meanwhile, cells subjected to STK33-RNAi showed
the reduction in cell volume, chromatin condensation,
and/or presence of apoptotic bodies, which were the typ-
ical morphological features of apoptosis. Whereas, cells
transfected with scrambled RNAi showed regularly pol-
ygonal shape, the normal morphology of Fadu cells.
These results indicated that STK33-RNAi lentiviral vec-
tor was not only successfully transfected into Fadu cells,
but exerted effective function on the cells as well. Western
Figure 2 Correlation of STK33 expression with clinicopathological parameters. (A) Representative images of STK33 IHC staining in different
differentiation types and corresponding H&E staining (Magnification × 400, Scale bars, 50 μm). (B) STK33 IHC score was significantly higher in
non-keratinizing type than that in keratinizing type shown in A. Moreover, STK33 IHC score was significantly correlated with tumor size (C) clinical
stages (D) lymph node metastasis (E). Data were expressed as the mean ± SD. * P < 0.05.
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cells transfected with STK33-RNAi was significantly
decreased than that in cells transfected with scram-
bled RNAi (P < 0.05), which suggested that STK33-
RNAi effectively suppressed STK33 expression in Fadu
cells.
As shown in Figure 3D, E the cell viability significantly
decreased with increase in the concentrations of PD98059
and the post-treatment time (P < 0.05) by MTT assay. The
obtained results revealed that exposure of Fadu cells to
5 μM PD98059 for 48 h exhibited the least effective
response. Furthermore, the exposure of Fadu cells to
STK33-RNAi and/or PD98059 resulted in a marked re-
duction of cell viability (P < 0.05), and of note, the effect
by STK33-RNAi was significantly potentiated by addition
of PD98059 (P < 0.05).
The effects of STK33-RNAi and PD98059 on morpho-
logical changes of Fadu cells were examined with the
dual staining of HO and PI. As illustrated in Figure 3F, G
the typical characteristics of apoptosis were presented,including cell shrinkage, chromatin condensation, and
apoptotic bodies. Quantitative analyses of the number of
apoptotic cells revealed that both STK33-RNAi and 5 μM
PD98059 led to a significant increase in apoptotic cells in
comparison to that in control group (P < 0.05) and, mean-
while, the number was markedly higher in group with
STK33-RNAi in combination with 5 μM PD98059 than
that in group exposure to anyone alone (P < 0.05), indicat-
ing that STK33-RNAi and PD98059 cooperatively induced
apoptosis in Fadu cells.
As depicted in Figure 3H, I the colony size of cells
subjected to any intervention was smaller than that of
control cells. In addition, quantitative analyses revealed
that the numbers of the formed colonies were markedly
reduced by STK33-RNAi, PD98059, and a combination of
both, compared with that by mock-RNAi. Of these inter-
ventions, the combination of STK33-RNAi with PD98059
led to form minimum number of clones, thereby display-
ing a synergistic effect of STK33-RANi and PD98059 on
colony formation of Fadu cells.
Figure 3 Effects of STK33-RNAi and PD98059 on Fadu cells and in vitro cell function test. (A) Cells with GFP signal were considered
successfully transfected. Increase of the green fluorescence in Fadu cells transfected with both STK33-RNAi and scrambled RNAi was correlated
with the post-transfection time, however, apoptosis (↑) was induced only in the cells subjected to STK33-RNAi (Magnification × 400). a) The scrambled
RNAi, 1 × 107 TU/ml, b) The STK33-RNAi, 1 × 107 TU/ml. (B) Transfection of STK33-RNAi into the cells led to a significant decrease in STK33 protein
expression compared with that in the mock-transfected cells. a) The scrambled RNAi, 1 × 107 TU/ml, b) STK33-RNAi, 1 × 107 TU/ml, c) STK33-RNAi,
1 × 108 TU/ml. (C) Data represent the mean ± SEM from three western blot analyses * P < 0.05. (D, E) MTT assay showed that the decrease in cell
viability with PD98059 appeared in a concentration- and time-manner and the decrease in cell viability with STK33-RNAi was correlated with the
post-transfection time. The effect exerted by STK33-RNAi was enhanced by PD98059. In addition, induction of apoptosis (↑) and reduction of colony
size in Fadu cells by STK33-RNAi and PD98059 were assessed by Ho.33342 and PI staining (F, Magnification × 200), and colony formation
(H, Magnification × 100, Scale bars, 50 μm), respectively. a) Control, b) 5 μM PD98059, c) STK33-RNAi, d) STK33-RNAi and 5 μM PD98059. Quantitative
analyses of the number of apoptotic cells (G) and colonies (I) in response to the different stimuli were shown. Data represented the mean ± SEM;
n = 3, * P < 0.05.
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expressions of Caspase-3, Bcl-2 and Ki-67 in Fadu cells
As both STK33-RNAi and PD98059 can induce apop-
tosis in Fadu cells, we further investigated the possible
mechanisms underlying this action via examination of
activities of certain typical genes relevant to apoptosis or
proliferation with quantitative RT-PCR and western blot.
STK33-RNAi markedly increased the mRNA and pro-
tein expressions of Caspase-3 in Fadu cells at 96 h post-
transfection and 5 μM PD98059 led to a trend towards
increase in Caspase-3 expression of but not reaching
significance (P > 0.05) compared with control. On the
other hand, a significant reduction of Bcl-2 and Ki-67
expressions in Fadu cells after exposure to STK33-RNAior 5 μM PD98059 were detected, compared with those
in control groups (P < 0.05). Furthermore, Bcl-2 and Ki-
67 expressions in Fadu cells subjected to STK33-RNAi
plus 5 μM PD98059 were lower than those in the cells
to treatment alone (P < 0.05). These data indicated
that STK33-RNAi and PD98059 exerted synergistic ef-
fects on the expressions of these aforementioned genes
(Figure 4).
Effects of STK33-RNAi and/or PD98059 on the suppression
of migration and invasion in Fadu cells, and the expressions
of relevant genes
To explore the effects of STK33 on migratory and inva-
sive activities of Fadu cells, in vitro invasion assessment
Figure 4 Effects of STK33-RNAi and/or PD98059 on mRNA and protein expressions of genes relevant to apoptosis and proliferation of
Fadu cells. Real-time PCR (A) and western blot (B, C) showed STK33-RNAi significantly increased the expression of Caspase-3 in Fadu cells at
96 h post-transfection. Meanwhile, STK33-RNAi markedly decreased the expressions of Bcl-2 and Ki-67 in Fadu cells, and the effects were potentiated
by PD98059. Results were shown as the means ± SEM, n = 3. *P < 0.05.
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Figure 5A-C, the number of migratory cells were signi-
ficantly reduced by both STK33-RNAi and PD98059
compared with that with scrambled RNAi (P < 0.05) and,
moreover, the effect by STK33-RNAi was significantly
potentiated by addition of PD98059 (P < 0.05). With re-
spect to the effect of STK33-RNAi on invasion, similar
results were achieved by this assay. These data implied
that STK33-RNAi compromised the migratory and invasive
capacity of Fadu cells.
As shown in Figure 5D-F, treatment of Fadu cells with
STK33-RNAi or 5 μM PD98059 significantly promoted
the E-Cadherin expression (P < 0.05) and markedly in-
hibited the Vimentin expression (P < 0.05) compared with
that in control. Simultaneously, STK33-RNAi plus 5 μM
PD98059 remarkably induced the E-Cadherin expression
in Fadu cells than that in group subjected to single inter-
vention (P < 0.05). As for the expression of Nm-23-H1,
either STK33-RNAi or 5 μM PD98059 similarly resulted
in an obvious elevation at mRNA and protein levels
in Fadu cells compared with that in control (P < 0.05).
Moreover, Nm-23-H1 expression was markedly higherin STK33-RNAi and 5 μM PD98059 group than that
in any one group (P < 0.05).
Effect of STK33-RNAi and/or PD98059 on STK33 and
ERK1/2 expressions in Fadu cells
To further determine the relationship between STK33
and ERK1/2 signaling pathway, the mRNA and protein
expressions of STK33 and ERK1/2 in Fadu cells in re-
sponse to STK33-RNAi and/or PD98059 were examined
by quantitative RT-PCR and western blot in Fadu cells.
As shown in Figure 6, PD98059 significantly inhibited
ERK1/2 expressions at both mRNA and protein levels in
Fadu cells compared with those in the scrambled RNAi-
tansfected cells and, also, PD98059 markedly reduced
STK33 expression (P < 0.05). On the other hand, STK33-
RNAi significantly decreased the mRNA and protein ex-
pressions of STK33 (P < 0.05) and, STK33-RNAi, however,
had no impact on ERK1/2 expression (P > 0.05).
Discussion
Previous studies on human somatic tumors have shown
that STK33 acts as a novel tumor gene [4,7,8]. However,
Figure 5 Effects of STK33-RNAi and PD98059 on migratory and invasive abilities of Fadu cells and relevant genes. Representative images
of cystal violet-stained migratory (A) and invasive (B) cells after exposure to the scrambled RNAi and STK33-RNAi, respectively (Magnification ×
100, Scale bars, 50 μm). a) Mock, b) 5 μM PD98059, c) STK33-RNAi, d) STK33-RNAi plus 5 μM PD98059. (C) Numbers of migratory and invasive cells
in response to different interventions. STK33-RNAi significantly increased the mRNA (D) and protein (E, F) expressions of E-Cadherin and Nm-23-H1, while,
PD98059 enhanced the effects and STK33-RNAi obviously decreased the Vimentin expressions. Results were shown as means ± SEM, n = 3. *P< 0.05.
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Figure 6 Alterations in mRNA and protein expressions of STK33 and ERK1/2 in Fadu cells in response to STK33-RNAi and/or PD98059.
Either real-time PCR (A) or western blots (B,C) showed that PD98059 markedly decreased both STK33 and ERK1/2 levels in Fadu cells, but, STK33-RNAi
only significantly diminished STK33 expressions. Data showed the mean ± SEM, n = 3, *P < 0.05.
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in different types of tumor are conflicting and the pos-
sible role of STK33 on human HSCC has not been
investigated to date. In the present study, strong STK33
immunostaining was noted in human HSCC, but, weak
staining was presented in corresponding normal tissues.
This indicates that STK33 over-expression may play a
crucial role in the pathogenesis of HSCC, which is con-
sistent with the findings in other types of tumor [4,7,19].
Meanwhile, we found that STK33 was abundantly ex-
pressed at both mRNA and protein levels, confirming the
activation of STK33 in Fadu cells. Keratinizing HSCC is
well differentiated and associated with a better prognosis,
whereas, non-keratinizing HSCC is poorly differentiated
and associated with a more aggressive course [13]. In the
present work, the expression of STK33 was markedly ele-
vated in non-keratinizing type than that in keratinizing
type. Therefore, the significance of the greater expression
of STK33 in non-keratinizing HSCC than in keratinizing
type is that STK33 might be related to the dedifferen-
tiation in HSCC. Moreover, statistical analyses showed
that there existed significant associations between STK33
expression in HSCC with tumor size, clinical stage, and
lymph node metastasis. These results indicate that aber-
rant expression of STK33 may promote the initiation and
progression of HSCC. Our findings highly support an
oncogenic role of STK33 in human HSCC, which sheds a
new light on the mechanisms underlying the occurrence
of HSCC.
To examine the effect of STK33 per se, the STK33
RNAi was generated and introduced into Fadu cell. Wefound that the cells transfected with STK33 RNAi not
only exhibited a marked reduction in STK33 protein ex-
pression, but also appeared the morphological change
compared with those in the mock RNAi-transfected cells,
indicating that the generated STK33 RNAi was effective.
Next, we concentrated on exploring whether STK33
knockdown alone or together with PD98059, had the po-
tential to alter the properties of Fadu cells and, if so, the
possible mechanism underlying such an action.
In this work, we demonstrated that either STK33-RNAi
or PD98059 remarkably reduced cell viability of Fadu cells,
implying that STK33-RNAi was able to inhibit the growth
of Fadu cells in vitro. Meanwhile, the exposure of Fadu
cells to STK33-RNAi led to cell destruction with specific
morphologic features, which were in accordance with
typical morphological characteristics of cells undergone
apoptosis. This indicates that STK33-RNAi exerts its cyto-
toxity on Fadu cells is mainly attributable to the induction
of apoptosis. Not only that, this cytotoxic effect was po-
tentiated by the administration of PD98059 at the mini-
mum dose, exhibiting a synergistic effect of the two
insults. Moreover, the ability of colony formation is ne-
cessary for a tumor cell growing to a micro- lesion and
furthermore developing into macro-lesion [20]. We found
STK33-RNAi caused a marked reduction in colony num-
ber of Fadu cells, which means STK33-RNAi may sup-
press the coloning proliferation of Fadu cells, while,
PD98059 may potentiate the effect. These data reveal that
STK33 is an important factor and that a cross-talk net-
work exists between STK33 and ERK1/2 in the regulation
of survival and proliferation in Fadu cells.
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from mitochondria to cytoplasm, which in turn activates
a series of other apoptosomes and, particularly, the acti-
vation of Caspase-3 responsible for the execution of the
apoptotic program in response to apoptotic signals [21].
In the present study, the activities of Caspase-3 were
remarkably up-regulated by STK33-RNAi, suggesting
that STK33 knockdown -induced apoptosis in Fadu cells
is depend on mitochondrial pathway. It is well known
that proteins of the Bcl-2 family, which generally either
repress apoptosis or promote apoptosis, play a key role
in controlling the activation of caspases [22]. In this
work, a decrease in expression of Bcl-2 were observed
after exposure to STK33-RNAi, indicating that STK33
knockdown triggers apoptosis by down-regulating the
activities of anti-apoptotic Bcl-2, thereby revealing an-
other mechanism underlying the action of STK33 knock-
down on Fadu cells. As Ki67 universally expresses among
proliferating cells and is absent in quiescent cells, it is
commonly used as a marker for the evaluation of cell pro-
liferation [23]. We found that STK33-RNAi significantly
suppressed Ki-67 expressions at mRNA and protein levels,
further revealing the inhibitory trait of STK33 knockdown
on Fadu cells. In addition, PD98059 acts cooperatively
with STK33-RNAi to affect the expressions of these genes,
providing additional proof for a cross-talk interaction
between STK33 and ERK1/2 in Fadu cells.
Tumor cell invasion and metastasis are complex pro-
cesses that involve multiple steps [19]. In the present
investigation, STK33 knockdown altered the migratory
and invasive phenotype of the cells. Similarly, such effects
by STK33-RNAi were enhanced with PD98059. Epithelial-
mesenchymal transition (EMT) is a process by which
epithelial cells lose their polarity and are converted to a
mesenchymal phenotype, which represents an important
pathway to mediate invasion and metastasis of tumors
[24]. A defining feature of EMT is a reduction in E-
Cadherin level and a concomitant induction of higher
expression of Vimentin [25]. It has been documented that
ERK1/2 pathway is involved in EGF-induced EMT and
PD98059 diminished the EGF-induced EMT in SBOT
cells [26,27]. As for the relationship between STK33 and
EMT, it was reported that STK33 exhibited autophospho-
rylation and phosphorylated the intermediate filament
protein Vimentin directly [28]. Our data revealed STK33-
RNAi not only blocked Vimentin expression but also sim-
ultaneously elevated E-Cadherin expression, implying
STK33-RNAi suppresses EMT through both of the two
aspects. Furthermore, the synergistic effects of STK33-
RNAi and PD98059 on the expressions of Vimentin and
E-Cadherin exist, suggesting STK33 may trigger EMT
involved in EKR1/2 pathway. Lastly, we demonstrated
STK33-RNAi significantly increased the Nm-23-H1 ex-
pression and the effect was enhanced by PD98059. Thissuggests that STK33-knockdown inhibits the invasion and
metastasis of Fadu cells via triggering the activity of
Nm-23-H1 gene, which is well known to possess anti-
metastasis trait in tumors [29]. These data indicate
that STK33 may promote metastasis in HSCC and in-
crease migration and invasion in Fadu cells via inducing
EMT by activating Vimentin and suppressing E-Cadherin,
and reducing Nm-23-H1 genes, while, EKR1/2 pathway is
involved in the process.
In view of the aforementioned findings that STK33-
RNAi and PD98059 act in close collaboration each other
on Fadu cells, we tried to seek out the direct evidence in
relation to STK33 and ERK1/2 pathway by the examin-
ation of STK33 and ERK1/2 expressions. In the present
study, we found that STK33-RNAi only markedly sup-
pressed STK33 expression but failed to impact ERK1/2
expression; however, PD98059 significantly reduced both
ERK1/2 and STK33 expressions at mRNA and protein
levels in Fadu cells. These findings suggest that ERK1/2
might directly mediate STK33 activity, implying that
STK33 is possibly a downstream of ERK1/2, which is
consistent with the previous findings [4]. However, it has
been reported that reduction of STK33 has no effect on
the expression of ERK1/2 [9], indicating that the exact
relationship between STK33 activity and ERK1/2 path-
way needs to be deciphered further.Conclusions
In conclusion, we identify that STK33 is a potential
oncogene and may be useful as a diagnostic marker for
HSCC. The findings from this work highlight the func-
tional role of STK33 that inhibits apoptosis, enhances
proliferation, promotes metastasis and invasion, as well
as triggers EMT, which is possibly related to ERK1/2 path-
way. Thus our study illuminates a novel axis that STK33
may induce tumorigenesis of human HSCC, and, perhaps,
serve as a valuable molecular target for treatment of
HSCC. Further study should be focused on the identifica-
tion of a direct substrate for STK33 so as to determine the
precise role of STK33 gene in the initiation and progres-
sion of cancer cells.Abbreviations
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